SG Americas Securities LLC Lowers Stock Position in Bioventus Inc. (NYSE:BVS)

SG Americas Securities LLC lessened its stake in shares of Bioventus Inc. (NYSE:BVS) by 29.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,822 shares of the company’s stock after selling 7,493 shares during the quarter. SG Americas Securities LLC’s holdings in Bioventus were worth $213,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of BVS. Renaissance Technologies LLC boosted its stake in Bioventus by 401.5% during the second quarter. Renaissance Technologies LLC now owns 503,175 shares of the company’s stock worth $2,893,000 after buying an additional 402,841 shares during the period. LSV Asset Management acquired a new stake in shares of Bioventus during the first quarter worth about $1,170,000. Panagora Asset Management Inc. acquired a new stake in shares of Bioventus during the second quarter worth about $787,000. Bank of Montreal Can acquired a new stake in shares of Bioventus during the second quarter worth about $774,000. Finally, American Century Companies Inc. lifted its position in shares of Bioventus by 289.5% during the second quarter. American Century Companies Inc. now owns 169,161 shares of the company’s stock worth $973,000 after purchasing an additional 125,736 shares in the last quarter. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Bioventus Stock Up 1.8 %

Shares of NYSE:BVS opened at $12.97 on Wednesday. The company has a quick ratio of 0.96, a current ratio of 1.33 and a debt-to-equity ratio of 1.82. Bioventus Inc. has a fifty-two week low of $2.97 and a fifty-two week high of $13.07. The firm’s 50 day moving average price is $10.74 and its 200 day moving average price is $7.66. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -37.06 and a beta of 0.90.

Bioventus (NYSE:BVS) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.07 by $0.12. Bioventus had a negative net margin of 7.82% and a positive return on equity of 14.39%. The company had revenue of $151.22 million for the quarter, compared to analysts’ expectations of $137.70 million. During the same quarter last year, the company earned $0.14 earnings per share. As a group, equities research analysts predict that Bioventus Inc. will post 0.4 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on BVS. Craig Hallum raised their target price on shares of Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a report on Friday, September 27th. Canaccord Genuity Group raised their target price on shares of Bioventus from $8.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, August 13th.

Insiders Place Their Bets

In related news, Director John A. Bartholdson acquired 80,000 shares of the business’s stock in a transaction on Friday, August 16th. The shares were bought at an average price of $8.55 per share, with a total value of $684,000.00. Following the completion of the acquisition, the director now owns 6,913,857 shares in the company, valued at $59,113,477.35. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Bioventus news, Director John A. Bartholdson bought 25,500 shares of the stock in a transaction dated Monday, August 19th. The shares were acquired at an average cost of $8.55 per share, for a total transaction of $218,025.00. Following the completion of the transaction, the director now owns 6,939,357 shares in the company, valued at approximately $59,331,502.35. The trade was a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director John A. Bartholdson bought 80,000 shares of the stock in a transaction dated Friday, August 16th. The shares were acquired at an average price of $8.55 per share, for a total transaction of $684,000.00. Following the completion of the transaction, the director now owns 6,913,857 shares of the company’s stock, valued at approximately $59,113,477.35. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. 32.90% of the stock is owned by corporate insiders.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.